Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
2.070
-0.310 (-13.02%)
Mar 31, 2025, 10:57 AM EDT - Market open

Mangoceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.620.730.01-
Revenue Growth (YoY)
-15.81%8083.16%--
Cost of Revenue
0.240.30-
Gross Profit
0.380.430-
Selling, General & Admin
5.546.3920.07
Operating Expenses
8.628.5520.07
Operating Income
-8.24-8.12-1.99-0.07
Interest Expense
-0.01--0.01-0
Interest & Investment Income
-0.01--
Other Non Operating Income (Expenses)
-0.45-1.1--
Pretax Income
-8.71-9.21-2-0.07
Earnings From Continuing Operations
-8.71-9.21-2-0.07
Minority Interest in Earnings
0---
Net Income
-8.71-9.21-2-0.07
Preferred Dividends & Other Adjustments
0.87---
Net Income to Common
-9.58-9.21-2-0.07
Shares Outstanding (Basic)
2111
Shares Outstanding (Diluted)
2111
Shares Change (YoY)
84.23%49.22%34.98%-
EPS (Basic)
-4.84-8.58-2.78-
EPS (Diluted)
-4.84-8.58-2.78-
Free Cash Flow
-4.86-7-1.39-0.07
Free Cash Flow Per Share
-2.46-6.52-1.93-0.13
Gross Margin
61.70%58.99%54.26%-
Operating Margin
-1337.90%-1109.84%-22279.70%-
Profit Margin
-1555.26%-1259.40%-22352.11%-
Free Cash Flow Margin
-789.74%-957.07%-15545.59%-
EBITDA
-7.51-8.09-1.99-
D&A For EBITDA
0.730.020-
EBIT
-8.24-8.12-1.99-0.07
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q